COMP <GO>
BSX vs UNH // EV/EBITDA & P/E VALUATION
Boston Scientific Corporation (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: BSX 6
— UNH 8
▲ EV/EBITDA & P/E VALUATION LEADER: BSX
LAST: $42.69 (+0.61%) • MKT CAP: $61.87B
valuation
15.8x
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BSX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BSX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.00% | 88.57% | -19.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.20% | 11.47% | -2.27 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 15.8x | 16.4x | -0.65 | BSX | /valuation <GO> |
| Free Cash Flow Yield | 5.91% | 6.48% | -0.57 | UNH | /fcf-yield <GO> |
| Operating Margin | 18.00% | 4.82% | +13.18 | BSX | /operating-margins <GO> |
| Net Profit Margin | 14.00% | 3.14% | +10.86 | BSX | /net-margins <GO> |
| Revenue Growth (YoY) | 19.90% | 6.46% | +13.44 | BSX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.77 | 3.12 | -0.35 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | BSX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.0 | 59.2 | -16.20 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.33 | +0.66 | BSX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.5x | 17.1x | +1.41 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $61.87B | $368.83B | -$306.96B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BSX REV | UNH REV | BSX GROSS % | UNH GROSS % | BSX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $20.07B | $447.57B | 69.0% | 88.7% | $3.66B | $16.07B |
| FY 2024 | $16.75B | $400.28B | 68.6% | 88.3% | $2.65B | $20.70B |
| FY 2023 | $14.24B | $371.62B | — | 89.6% | $1.86B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BSX // BETA 0.99
UNH // BETA 0.33